| Market Capitalization (Millions $) |
115 |
| Shares
Outstanding (Millions) |
70 |
| Employees |
10 |
| Revenues (TTM) (Millions $) |
0 |
| Net Income (TTM) (Millions $) |
-38 |
| Cash Flow (TTM) (Millions $) |
-14 |
| Capital Exp. (TTM) (Millions $) |
0 |
Eyenovia Inc
Eyenovia Inc. is a clinical stage biopharmaceutical company that specializes in developing and commercializing transformative ophthalmic products for patients. The company focuses on innovation and technology, encompassing micro-dosing drug delivery systems and therapeutic molecules. Eyenovia was founded in 2014 and is headquartered in New York, United States.
The company's mission is to address the unmet needs of the ophthalmic market and provide patients with better solutions for the treatment and management of eye diseases. Eyenovia's innovative technology aims to deliver precise doses of medications to the eye, improving efficacy, safety, and compliance.
Eyenovia has a pipeline of products focused on three areas- myopia, presbyopia, and mydriasis. Myopia is a common eye condition that causes nearsightedness, and the company's lead product candidate called MicroPine is specifically designed to treat it. MicroPine is a micro-dosing eye drop that delivers low-dose atropine to the eye to prevent the progression of myopia.
Presbyopia, another eye condition causing age-related farsightedness, is another area of interest for Eyenovia. The company's product candidate, MicroLine, is a micro-dosing eye drop that delivers pilocarpine HCl and can improve near vision in patients with presbyopia.
The third area of focus for Eyenovia is mydriasis, which is the dilation of the pupil that allows for a more thorough examination of the eye. The company's product candidate, MicroStat, is a micro-dosing eye drop that delivers phenylephrine and tropicamide for mydriasis.
Besides its pipeline of products, Eyenovia has a licensing agreement with Eton Pharmaceuticals for MicroTears in the United States, and the company also holds numerous patents and intellectual property related to its technology and products.
Eyenovia has garnered several awards and recognitions for its innovative solutions and product pipeline. These include the 2019 Ophthalmology Innovation Summit (OIS) Innovation Showcase Winner, the 2019 Red Herring Top 100 North America Winner, and the 2018 R&D 100 Award Winner.
Overall, Eyenovia is a company committed to using innovative technology to develop and commercialize transformative ophthalmic products that address unmet needs in the market. The company is well-positioned to make a significant impact on the ophthalmic industry and improve the quality of life for patients with eye diseases.
Company Address: 295 Madison Avenue, Suite 2400 NEW YORK 10017 NY
Company Phone Number: 393-6684 Stock Exchange / Ticker: NASDAQ EYEN
|
4.38% 